Elecoglipron: The Oral GLP-1 Pill Heading to Phase 3
Author
glp winnerDate Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
Elecoglipron is an experimental once-daily GLP-1 pill that performed well in a mid-stage study and is now moving into the large, final round of testing before a company can ask for FDA approval (The Lancet). It is not approved and you cannot get it yet, but it is one more sign that the weight-loss pill race is heating up, which over time could mean more choices for patients (AstraZeneca).
Who This Helps
This is for anyone tracking what is coming next in GLP-1 treatment, especially people who would prefer a pill to a weekly shot and want to know which options are real today and which are still years away. It is also for caregivers trying to separate hype from what is actually available.
What Is Elecoglipron?
Elecoglipron is an experimental once-daily pill being developed by the drugmaker AstraZeneca. It is a GLP-1 receptor agonist, the medical term for medicines that act on a gut-hormone receptor to curb appetite and help manage blood sugar, and it is the same broad class as today's GLP-1 medications (AstraZeneca).
It is also a small-molecule pill, meaning it is built from simpler chemistry than the injectable versions, which tend to be harder and costlier to manufacture. That difference is part of why drugmakers are racing to bring pills to market.
What the Early Trial Found
In a Phase 2 study, the mid-stage testing that checks whether a drug works and is reasonably safe, elecoglipron was tested in 310 adults with obesity or excess weight. People on the highest dose lost about 10.5% of their body weight at 26 weeks, compared with about 0.6% for those on a placebo, and weight loss continued to about 11.8% by 36 weeks (The Lancet).
The most common side effects were mild to moderate stomach-related issues, the same kind seen with other GLP-1 medicines, and the study reported no liver safety concerns and little low blood sugar (STAT). These are early results in a few hundred people, so they need to hold up in much larger studies before they mean anything for everyday care.
What Phase 3 Means and What Happens Next
Phase 3 is the final and largest stage of testing, where a drug is studied in thousands of people over a longer time to confirm it works and to catch rarer side effects, and the FDA reviews those results before any approval (AstraZeneca). AstraZeneca is moving elecoglipron into a broad Phase 3 program that covers obesity and type 2 diabetes, along with trials looking at heart and kidney outcomes.
What this means for you: this is a milestone, not a finish line. Even in the best case, large trials and an FDA review take time, so elecoglipron is a candidate to watch rather than an option to ask your doctor about today.
How It Compares to Pills You Can Get Today
Two GLP-1 pills are already FDA approved. The Wegovy pill (oral semaglutide) produced about 16.6% mean weight loss when taken as directed in its trial (AJMC), and Foundayo (orforglipron) reached up to about 12.4% in its trial (Eli Lilly).
Among injections, tirzepatide led to about 20.2% weight loss versus about 13.7% for semaglutide in a head-to-head trial (New England Journal of Medicine).
What this means for you: elecoglipron's roughly 10.5% came from a shorter, mid-stage study and was not measured head-to-head against these options, so the numbers are not a fair apples-to-apples comparison yet. The injectable form of Zepbound (tirzepatide) still shows the highest average weight loss of the group.
Why AstraZeneca Joining the Race Could Help You
The competition may matter more than the drug itself. Today the obesity-drug market runs mostly on two companies, Novo Nordisk and Eli Lilly, so a serious push from AstraZeneca would add a rare third major player, and more competition tends to widen access and put pressure on price over time (CNBC). It does not guarantee a lower bill, but a market with several real competitors behaves differently than one run by two.
Timing keeps it honest, though. If elecoglipron clears its trials, it would likely not reach the market until around 2029, so the competition it brings is a slow build, not a change you will feel this year.
While the pipeline fills out, the move that helps you now is to weigh what is already on the shelf. You can compare today's providers and transparent pricing, including HSA and FSA options, with the GLP Winner provider survey.
Final Takeaway
Elecoglipron is one more company betting on a weight-loss pill, and the competition it brings may end up mattering more than the pill itself. For now, it is a headline, not a prescription.
If you want a pill you can start now, the Wegovy pill is approved and available today, and Foundayo is a second approved pill to ask your doctor about.
There is no reason to put your plan on hold for a drug that is likely years from a pharmacy shelf. Weigh what is in front of you with your prescriber and pick what fits your life.
Keep half an eye on elecoglipron as its trials play out, and let it earn its place if the larger studies hold up.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Sources
Keep Reading
Two GLP-1 pills are now FDA approved, with more coming. See how oral options could change access, what they cost, and how they compare to shots.
Retatrutide is not FDA approved, but some clinics sell it anyway. See what the science shows and why approval status matters for you.
A clear look at the next wave of GLP-1 drugs in 2026 — launches, filings, access changes and what patients and payers should know.
Categories
Curated by
